Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective use of molecular minimal residual disease for risk stratification in children and adolescents with acute lymphoblastic leukemia : Long-term results of the AIEOP-BFM ALL 2000 trial in Austria.
Ronceray L, Dworzak M, Dieckmann K, Ebetsberger-Dachs G, Glogova E, Haas OA, Jones N, Nebral K, Moser R, Lion T, Meister B, Panzer-Grümayer R, Strehl S, Peters C, Pötschger U, Urban C, Mann G, Attarbaschi A; Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Ronceray L, et al. Among authors: panzer grumayer r. Wien Klin Wochenschr. 2023 Aug 3. doi: 10.1007/s00508-023-02249-6. Online ahead of print. Wien Klin Wochenschr. 2023. PMID: 37535134
Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA. Attarbaschi A, et al. J Clin Oncol. 2008 Jun 20;26(18):3046-50. doi: 10.1200/JCO.2008.16.1117. J Clin Oncol. 2008. PMID: 18565891
Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements.
Attarbaschi A, Pisecker M, Inthal A, Mann G, Janousek D, Dworzak M, Pötschger U, Ullmann R, Schrappe M, Gadner H, Haas OA, Panzer-Grümayer R, Strehl S; Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Attarbaschi A, et al. Br J Haematol. 2010 Jan;148(2):293-300. doi: 10.1111/j.1365-2141.2009.07944.x. Epub 2009 Oct 11. Br J Haematol. 2010. PMID: 19821827 Free article.
Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
Pichler H, Möricke A, Mann G, Teigler-Schlegel A, Niggli F, Nebral K, König M, Inthal A, Krehan D, Dworzak MN, Janousek D, Harbott J, Schrappe M, Gadner H, Strehl S, Haas OA, Panzer-Grümayer R, Attarbaschi A; Berlin-Frankfurt-Münster (BFM) Study Group. Pichler H, et al. Br J Haematol. 2010 Apr;149(1):93-100. doi: 10.1111/j.1365-2141.2009.08059.x. Epub 2010 Jan 13. Br J Haematol. 2010. PMID: 20067563 Free article. Clinical Trial.
Treatment outcome of CRLF2-rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP-BFM and UK NCRI-CCLG study groups.
Attarbaschi A, Morak M, Cario G, Cazzaniga G, Ensor HM, te Kronnie T, Bradtke J, Mann G, Vendramini E, Palmi C, Schwab C, Russell LJ, Schrappe M, Conter V, Mitchell CD, Strehl S, Zimmermann M, Pötschger U, Harrison CJ, Stanulla M, Panzer-Grümayer R, Haas OA, Moorman AV; Associazione Italiana di Ematologia ed Oncologia Pediatrica (AIEOP)-Berlin-Frankfurt-Münster (BFM) Study Group and National Cancer Research Institute (NCRI)-Children's Cancer and Leukaemia (CCLG) Study Group. Attarbaschi A, et al. Br J Haematol. 2012 Sep;158(6):772-7. doi: 10.1111/j.1365-2141.2012.09221.x. Epub 2012 Jul 23. Br J Haematol. 2012. PMID: 22816614 Free article.
The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate--a population-based analysis of 25 years of the Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group.
Pichler H, Reismüller B, Steiner M, Dworzak MN, Pötschger U, Urban C, Meister B, Schmitt K, Panzer-Grümayer R, Haas OA, Attarbaschi A, Mann G; Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group. Pichler H, et al. Br J Haematol. 2013 May;161(4):556-65. doi: 10.1111/bjh.12292. Epub 2013 Mar 11. Br J Haematol. 2013. PMID: 23480776 Free article.
Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial.
Attarbaschi A, Panzer-Grümayer R, Mann G, Möricke A, König M, Mecklenbräuker A, Teigler-Schlegel A, Bradtke J, Harbott J, Göhring G, Stanulla M, Schrappe M, Zimmermann M, Haas OA; Austrian and German ALL-BFM (Berlin-Frankfurt-Münster) Study Group. Attarbaschi A, et al. Klin Padiatr. 2014 Nov;226(6-7):338-43. doi: 10.1055/s-0034-1387795. Epub 2014 Nov 28. Klin Padiatr. 2014. PMID: 25431866 Clinical Trial.
62 results